Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Aflac (AFL) upgraded to Neutral from Underperform at BofA/Merrill with analyst Seth Weiss saying Aflac has underperformed the group over the past year while improving its rate of cash flow generation to over 80% of operating earnings in 2014-2016 from 25% of operating earnings in 2011-2013 and has $2.4B of excess capital capacity. 2. Jazz Pharmaceuticals (JAZZ) upgraded to Buy from Neutral at Janney Capital with analyst Ken Trbovich saying the company's settlement with Hikma over Xyrem eliminates a major overhang. While the deal allows Hikma to sell an authorized generic in 2023, about three years earlier than previous settlements with other generic filers, it eliminates the risk of an earlier launch and provides Jazz with a "meaningful royalty" on sales, Trbovich noted. 3. PacWest Bancorp (PACW) upgraded to Strong Buy from Outperform at Raymond James with analyst David Long citing the recent pullback in shares, the encouraging investor meeting last month, and increased investor interest in deposit franchises. 4. Abiomed (ABMD) upgraded to Overweight from Neutral at Piper Jaffray with analyst Matt O'Brien saying the company's premium valuation is warranted give its "strong revenue growth outlook, non-existent competition, and considerable earnings power." 5. Marvell (MRVL) assumed with a Buy from Neutral at MKM Partners. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.